Results for this period
Third quarter1 July 2025 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Orders for bio-manufacturing support services remained strong after launch, achieving the annual sales target of ¥100 million. This was partly offset by a decline in functional materials development support services due to large-scale clinical trial revenue shifting to the fourth quarter, and a decline in life sciences research support services due to fewer large projects in the domestic academic sector and sluggish overseas sales.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥1,107 million (YoY -12.6%) |
| Operating profit | ¥208 million (YoY -41.1%) |
| Ordinary income | ¥209 million (YoY -38.8%) |
| Profit attributable to owners of the parent | ¥165 million (YoY -45.6%) |
| Net income per share | ¥29.35 |
| Equity ratio | End of the current fiscal period 82.4 / End of previous period 79.6 |
| Total assets | ¥2,287 million |
| Net assets | ¥1,884 million |
| Full-year earnings forecast | Net Sales ¥1,420 million (YoY -2.4%) / Operating profit ¥210 million (YoY -15.8%) / Ordinary income ¥210 million (YoY -12.9%) / Net income ¥200 million (YoY -22.0%) |
| Annual Dividend Forecast | ¥15 → ¥18（+20.0%） |
| Depreciation and amortization | ¥83,204 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥17,993 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name No applicable matters |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 5,919,797 |
| Treasury Shares at Period-End | 356,118 |
| Factors Behind Changes in Business Performance | Orders for bio-manufacturing support services remained strong after launch, achieving the annual sales target of ¥100 million. This was partly offset by a decline in functional materials development support services due to large-scale clinical trial revenue shifting to the fourth quarter, and a decline in life sciences research support services due to fewer large projects in the domestic academic sector and sluggish overseas sales. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from functional materials development support services was below the prior-year level for the third quarter because revenue associated with a large-scale clinical trial is scheduled for the fourth quarter. Revenue from life sciences research support services also decreased because large projects in the domestic academic sector declined and overseas sales remained sluggish. Operating profit was affected by the decline in revenue, although development costs decreased following the completion of joint research projects and for other reasons.